Takeda is ready to auction off a PhIII favorite at Shire to clear the last hurdles to a $62B buyout

For sale: A promising inflammatory bowel disease drug now in Phase III studies for ulcerative colitis and Crohn’s disease, once described by the executive team at Shire as one of the most precious “gems’ in its late-stage pipeline. Inquire at Takeda.